$XGN News

Exagen: The Path To Profitability Just Became More Credible

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen (NASDAQ:XGN) Beats Q2 Estimates and Raises Full-Year Guidance

Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est

Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8

Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests Alone

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Exagen (XGN) Q1 2026 Earnings Transcript

Exagen Inc. Q1 2026 Earnings Call Summary

Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...

BTIG Maintains Buy on Exagen, Lowers Price Target to $8

Exagen Inc. 2026 Q1 - Results - Earnings Call Presentation

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

Exagen Q1 Earnings Call Highlights

Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses

Exagen Inc. (NASDAQ:XGN) Soars on Q1 2026 Earnings Beat as Record Revenue and Narrowed Loss Fuel Pre-Market Rally

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen Inc. Reports First Quarter 2026 Results

Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M Est